Comparative Pharmacology
Head-to-head clinical analysis: PARAFLEX versus ROBAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARAFLEX versus ROBAXIN.
PARAFLEX vs ROBAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Centrally acting muscle relaxant; inhibits polysynaptic reflexes at the spinal cord level, possibly by depressing the central nervous system.
Centrally acting muscle relaxant; depresses polysynaptic reflexes at spinal cord and supraspinal levels, possibly via glycine receptor agonism and GABAergic modulation.
250-500 mg orally once daily, may increase to 500 mg twice daily if needed. Maximum 500 mg/day.
1500 mg orally 4 times daily, or 750 mg orally every 4 hours as needed. Maximum 6 g/day. For IV use: 1 g (10 mL) as a single intravenous injection or infusion.
None Documented
None Documented
Terminal elimination half-life is approximately 2–3 hours, allowing for multiple daily dosing.
1-2 hours in adults; clinically, multiple daily dosing required to maintain effect.
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of an oral dose; fecal excretion accounts for about 20%.
Renal excretion of metabolites accounts for 99% of elimination; <1% excreted as unchanged drug in urine.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant